This webinar takes place on Tuesday January 28th between 16.00 and 16.30 CET / 15.00-15.30 GMT / 10.00-10.30 AM EST.

Follow the link to register for the webinar. Please note that the presentation will be given during the live event only and on demand viewing at a later date will not be possible. Contact us for any questions.

 

REGISTER FOR LIVE WEBINAR

 

THIS WEBINAR IS ARRANGED BY CELLECTRICON AB. FOR MORE INFORMATION ON THE HANDLING OF YOUR PERSONAL INFORMATION, SEE OUR PRIVACY POLICY.

Abstract:

Neuroplasticity, the brain’s ability to reorganize itself by forming new neuronal connections, is crucial for learning, memory, and recovery from brain injuries. Changes in neuroplasticity are implicated in various neurological, neuropsychiatric, and neurodegenerative disorders.

Cellectricon’s in vitro neuroplasticity assays combine high-content analysis (HCA) and primary cortical cultures. Among these assays, the neuritogenesis assay is designed to quantify compound effects on complex, single-cell parameters of neurites with exceptional reproducibility. Ideal for large-scale screening, the assay’s high capacity and reliability make it a powerful tool in drug discovery.

This webinar will provide a comprehensive overview, showcasing how robust data generation can facilitate the identification of compounds that promote neuronal plasticity, offering promising therapeutic avenues across multiple disease areas.

Presented by:

Susanne Lardell

Susanne joined Cellectricon in 2012 as External Collaborations Manager and Senior Scientist. In her role, she designs and drives drug discovery projects for clients, mainly in the areas of neuroplasticity and neurodegeneration. Prior to joining Cellectricon, she was a Senior Research Scientist at AstraZeneca working in the department of Drug metabolism and Pharmacokinetics. Susanne has a MSc in Pharmaceutical Bioscience from University of Gothenburg, Sweden.